Abstract
Background
Although pancreatic cancer is the fourth leading cause of cancer death, few studies have evaluated population-based trends in diagnosis, management, and outcome.
Methods
We used the Surveillance, Epidemiology, and End Results (SEER) registry to evaluate treatment trends and outcomes for patients 18 or older with pancreatic adenocarcinoma diagnosed from 1988 through 2002.
Results
We identified 38,073 patients diagnosed with pancreatic cancer over this 15-year period; the age-adjusted incidence did not change over this period. Most patients were diagnosed with metastatic disease (50.3%), few of whom underwent irradiation or cancer-directed surgery (CDS). For patients with localized or regional disease (32.9%), 53% underwent some form of treatment. Importantly, the rate of CDS increased from 19% in 1988 to 35% in 2002 (P < 0.0001). In multivariate analysis, young age, married status, and localized disease were associated with significantly higher CDS rates. For patients with nonmetastatic disease, 2-year survival rate increased from 8% in 1988 to 15% in 2000. For patients with non-metastatic cancer who survived at least 3 months, CDS was associated with a significantly higher 2-year survival rate (CDS, 36%; non-CDS, 10%). Conclusions: Most patients with pancreatic cancer, even at the end of our 15-year study period, still presented with metastatic disease, and the survival rate for such patients did not change in a meaningful way over time. The proportion of patients with nonmetastatic pancreatic cancer who underwent potentially curative surgery increased over time in the U.S.; the 2-year survival rate for such patients improved, but remained poor.
Similar content being viewed by others
References
Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin. 1999; 49:8–31
O’Connell JB, Maggard MA, Ko CY. Cancer-directed surgery for localized disease: decreased use in the elderly. Ann Surg Oncol. 2004; 11:962–9
Castellanos J, Manifacio G, Lillehei RC, Shatney CH. Total pancreatectomy for ductal carcinoma of the head of the pancreas: current status. Am J Surg 1976; 131:595–8
Crile G Jr. The advantages of bypass operations over radical pancreatoduodenectomy in the treatment of pancreatic carcinoma. Surg Gynecol Obstet. 1970; 130:1049–53
Crist DW, Sitzmann JV, Cameron JL. Improved hospital morbidity, mortality, and survival after the Whipple procedure. Ann Surg 1987; 206:358–65
Janes RH, Jr., Niederhuber JE, Chmiel JS, et al. National patterns of care for pancreatic cancer. Results of a survey by the Commission on Cancer. Ann Surg 1996; 223:261–72
Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985–1995, using the National Cancer Database. J Am Coll Surg 1999; 89:1–7
Surveillance, Epidemiology, and End Results (SEER). About SEER. National Cancer Institute. Available at: http://www.seer.cancer.gov/about/
Linder S, Bostrom L, Nilsson B. Pancreatic cancer in Sweden 1980–2000: a population-based study of hospitalized patients concerning time trends in curative surgery and other interventional therapies. J Gastrointest Surg. 2006; 10:672–8
Rios G, Conrad A, Cole D, Adams D, Leveen M, O’Brien P, Baron P. Trends in indications and outcomes in the Whipple procedure over a 40-year period. Am Surg 1999; 65:889–93
Conlon KC, Klimstra DS, Brennan MF. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg 1996; 223:273–9
Christein JD, Kendrick ML, Iqbal CW, Nagorney DM, Farnell MB. Distal pancreatectomy for resectable adenocarcinoma of the body and tail of the pancreas. J Gastrointest Surg 2005; 9:922–7
Magistrelli P, Antinori A, Crucitti A, et al. Prognostic factors after surgical resection for pancreatic carcinoma. J Surg Oncol 2000; 74:36–40
Krysa J, Miller M, Kukreja N, Steger A. Pancreatic cancer–is an aggressive approach justified? Ann R Coll Surg Engl 2005; 87:163–6
Niederhuber JE, Brennan MF, Menck HR. The National Cancer Data Base report on pancreatic cancer. Cancer. 1995; 76:1671–7
Picozzi VJ, Kozarek RA, Traverso LW. Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg. 2003 ; 85(5):476–80
Acknowledgements
The authors thank Mary Knatterud, Ph.D. for her editorial assistance.
Author information
Authors and Affiliations
Corresponding author
Additional information
This research was supported, in part, by the University of Minnesota Comprehensive Cancer Center. Dr. Tuttle is supported by a University of Minnesota Cancer Center Clinical Scholar Award. Dr. Baxter is supported by an American Society of Clinical Oncology Career Development Award.
This research was presented during the plenary session of the 2006 Society of Surgical Oncology Annual Meeting.
Rights and permissions
About this article
Cite this article
Baxter, N.N., Whitson, B.A. & Tuttle, T.M. Trends in the Treatment and Outcome of Pancreatic Cancer in the United States. Ann Surg Oncol 14, 1320–1326 (2007). https://doi.org/10.1245/s10434-006-9249-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-006-9249-8